481 related articles for article (PubMed ID: 28880380)
1. Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS Study.
Lipton RB; McGinley JS; Shulman KJ; Wirth RJ; Buse DC
Headache; 2017 Nov; 57(10):1570-1582. PubMed ID: 28880380
[TBL] [Abstract][Full Text] [Related]
2. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
[TBL] [Abstract][Full Text] [Related]
3. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
[TBL] [Abstract][Full Text] [Related]
4. Evaluating Mean Level and Within-Person Consistency in Migraine Pain Intensity and Migraine-Related Disability for AVP-825 vs Oral Sumatriptan: Results from the COMPASS Study, A Randomized Trial.
McGinley JS; Buse DC; Shulman KJ; Wirth RJ; Hugentobler E; Lipton RB
Headache; 2019 Jul; 59(7):1002-1013. PubMed ID: 31062349
[TBL] [Abstract][Full Text] [Related]
5. AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial.
Lipton RB; McGinley JS; Shulman KJ; Silberstein SD; Wirth RJ; Buse DC
Headache; 2018 Feb; 58(2):229-242. PubMed ID: 29034453
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
Cady RK; McAllister PJ; Spierings EL; Messina J; Carothers J; Djupesland PG; Mahmoud RA
Headache; 2015 Jan; 55(1):88-100. PubMed ID: 25355310
[TBL] [Abstract][Full Text] [Related]
7. A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine.
Cady R
Expert Opin Drug Deliv; 2015; 12(9):1565-77. PubMed ID: 26119828
[TBL] [Abstract][Full Text] [Related]
8. Sumatriptan Nasal Powder: A Review in Acute Treatment of Migraine.
Al-Salama ZT; Scott LJ
Drugs; 2016 Oct; 76(15):1477-1484. PubMed ID: 27681528
[TBL] [Abstract][Full Text] [Related]
9. A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine.
Silberstein SD
Expert Opin Drug Saf; 2018 Jan; 17(1):89-97. PubMed ID: 28994319
[TBL] [Abstract][Full Text] [Related]
10. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
[TBL] [Abstract][Full Text] [Related]
11. AVP-825: a novel intranasal delivery system for low-dose sumatriptan powder in the treatment of acute migraine.
Silberstein S
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):821-832. PubMed ID: 28605258
[TBL] [Abstract][Full Text] [Related]
12. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine.
Diamond S; Elkind A; Jackson RT; Ryan R; DeBussey S; Asgharnejad M
Arch Fam Med; 1998; 7(3):234-40. PubMed ID: 9596457
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine.
Rao AS; Gelaye B; Kurth T; Dash PD; Nitchie H; Peterlin BL
Headache; 2016 Feb; 56(2):331-40. PubMed ID: 26840902
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study.
Carpay J; Schoenen J; Ahmad F; Kinrade F; Boswell D
Clin Ther; 2004 Feb; 26(2):214-23. PubMed ID: 15038944
[TBL] [Abstract][Full Text] [Related]
15. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168
[TBL] [Abstract][Full Text] [Related]
16. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
[TBL] [Abstract][Full Text] [Related]
18. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
[TBL] [Abstract][Full Text] [Related]
19. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
[TBL] [Abstract][Full Text] [Related]
20. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device.
Luthringer R; Djupesland PG; Sheldrake CD; Flint A; Boeijinga P; Danjou P; Demazières A; Hewson G
J Pharm Pharmacol; 2009 Sep; 61(9):1219-28. PubMed ID: 19703372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
